Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
NCT06574360Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Sep 2024
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia (2 arms), sponsored by China Medical University Hospital. Primary endpoint: Positive and Negative Syndrome Scale at week 8. Started Sep 2024; status: recruiting.
02
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06574360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574360.